Gapping up
In reaction to earnings/guidance:
- APLS +10.9%, MESO +6.3%, AER +5.6%, CNA +5.2%, SYM +4.3%, EGRX +3.1% (guidance), PSO +0.8%, L +0.5%
Other news:
- APLS +12.1% (provides update on review of rare safety events with SYFOVRE (pegcetacoplan injection) for Geographic Atrophy; reports SYFOVRE continued to demonstrate increasing treatment effects over 30 months in patients with geographic atrophy)
- ANNX +8.7% (presents ARCHER trial results at ASRS 2023 highlighting potential of ANX007 as a differentiated treatment for geographic atrophy)
- ACHR +6.9% (Archer Aviation and US Air Force enter into contracts worth up to $142 million)
- SOL +3.9% (recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group)
- RDHL +3.1% (RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA)
- AGR +2.7% (announces installation of the first offshore substation in the US)
- BSAQ +1.8% (VinFast's Registration Statement in connection with its proposed business combination with Black Spade declared effective by SEC)
- FOXA +1.4% (Fox Corporation and Flutter Entertainment announce close of FOX Bet)
- PBR +1.4% (approved the revision of the Policy for Disclosure of Material Act or Fact and Securities Trading; also also approved the improvement of its Shareholder Remuneration Policy)
- PRO +1.1% (positive Barron's article)
- ZYXI +1.1% (Zynex and shareholders revised Lock-up Agreements)
- JJSF +1% (positive Barron's article)
Analyst comments:
- GDRX +6.1% (upgraded to Outperform from Market Perform at TD Cowen)
- CRSR +3.2% (upgraded to Outperform from Neutral at Wedbush)
- ADBE +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CVX +1.6% (upgraded to Buy from Neutral at Goldman)
- NVCR +0.7% (upgraded to In-line from Underperform at Evercore ISI)